OPEN END TURBO CALL-OPTIONSSCHEIN MIT SL - NOVO-NORDISK B | Market Closed - Bid/Ask 07:52:45 2024-05-31 EDT | Pre-market 01:47:32 | |||
| 18.78 EUR | -0.11% |
|
18.94 | +0.83% |
| 1 month | +6.77% | ||
| 3 months | +16.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 18.78 | -0.11% |
| 24-05-30 | 18.8 | +2.68% |
| 24-05-29 | 18.31 | -2.03% |
| 24-05-28 | 18.69 | -0.59% |
| 24-05-27 | 18.8 | +0.05% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 07:52 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SD7EZS |
| ISIN | DE000SD7EZS0 |
| Date issued | 2021-04-06 |
| Strike | 228.3 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 18.8 € |
|---|---|
| Lowest since issue | 0.26 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- Certificat
